Investigating PF-07985045 for advanced solid tumors with KRAS mutations

A PHASE 1 OPEN-LABEL STUDY OF PF-07985045 AS A SINGLE-AGENT AND IN COMBINATION WITH OTHER ANTI-CANCER AGENTS IN PARTICIPANTS WITH ADVANCED SOLID TUMORS

This study is testing a new drug called PF-07985045 to see if it can help people with advanced solid tumors that have a KRAS mutation, especially those who haven't had success with standard treatments.

Quick facts

• Phase: Phase 1
• Study type: Interventional
• Enrollment: 190 (estimated)
• Ages: 18 Years and up
• Sex: All
• Sponsor: Pfizer (Industry-sponsored)
• Drugs / interventions: cetuximab, bevacizumab, pembrolizumab, sasanlimab, chemotherapy, radiation, prednisone
• Locations: 10 sites (Fayetteville, Arkansas and 9 other locations)
• Trial ID: NCT06704724 on ClinicalTrials.gov

What this trial studies

This study aims to evaluate the safety and efficacy of the investigational drug PF-07985045, both alone and in combination with other anti-cancer therapies, in patients with advanced solid tumors that have a KRAS gene mutation. The trial will determine the optimal dosage of the medication while focusing on specific cancer types, including non-small cell lung cancer, colorectal cancer, and pancreatic ductal adenocarcinoma. Participants must have measurable lesions and have progressed on standard treatments, ensuring a targeted approach to their care.

Who should consider this trial

Good fit: Ideal candidates include individuals with advanced, unresectable solid tumors that have a documented KRAS gene mutation.

Not a fit: Patients without a KRAS mutation or those with previously treated G12C mutations may not benefit from this study.

Why it matters

Potential benefit: If successful, this study could provide a new treatment option for patients with advanced solid tumors that have specific genetic mutations.

How similar studies have performed: Other studies targeting KRAS mutations have shown promise, indicating potential for success with this approach.

Eligibility criteria

Inclusion Criteria:

* Histological or cytological diagnosis of advanced, unresectable, and/or metastatic or relapsed/refractory solid tumor.

  * Note for PDAC: Only participants with the histologic type of adenocarcinoma of the pancreas are allowed to enroll. For PDAC, if loco-regional disease is present, must also have metastatic disease.
  * Note for NSCLC: If a driver mutation is present, the participant was resistant or intolerant of precision medicine therapy (eg, inhibitors of EGFR, ALK, ROS1, or others).
* ECOG PS 0 or 1
* Presence of at least 1 measurable lesion based on RECIST version 1.1 that has not been previously irradiated.
* Documentation of mutated KRAS gene

  1. KRAS mutations of any variant except previously treated G12C, present in tumor tissue or blood
  2. If the participant received KRAS G12C inhibitor treatment previously, the KRAS mutation status must be other than G12C
* Part 1: Participant must have progressed on standard treatment(s) for which no additional, effective therapy is available.

  1. PDAC (2-3L): Participants must have received and radiologically progressed on prior lines of systemic therapy for metastatic pancreatic adenocarcinoma. If participants received prior neoadjuvant or adjuvant chemotherapy and progressed within 6 months of the last dose, then this should be considered as a prior line of systemic therapy.
  2. NSCLC (2-3L): Participants must have received prior lines of anti-cancer treatment and progressed on at least a platinum-containing chemotherapy regimen and checkpoint inhibitor therapy; for participants with EGFR, ALK, or other genomic tumor alterations, participants must have progressed on approved therapy for these alterations.
  3. CRC (2-3L): Participants must have had one or two prior systemic treatment regimens for mCRC. For either one or two prior treatments, these regimens must have included a fluoropyrimidine, oxaliplatin, or irinotecan; for one prior treatment, exposure to VEGF/VEGF receptor (VEGFR) inhibitor is optional.
  4. other tumors: Participants, in the judgment of the investigator, must have progressed or become intolerant to all available standard therapies, or have refused such therapy.
* Part 2:

  1. PDAC (1L) Cohort A2: Participants must not have received prior chemotherapy for metastatic disease. Participant could have received neoadjuvant therapy, adjuvant therapy, or adjuvant chemo-radiotherapy, as long as relapse did not occur within 6 months of completing these forms of adjuvant treatment. If so, the relapse within 6 months would be considered a line of therapy; the participant would be considered 2L, and not 1L.
  2. CRC (2-3L) Cohort B2: Participants must have had one or two prior systemic treatment regimens for mCRC. For either one or two prior treatments, these regimens must have included a fluoropyrimidine, irinotecan, oxaliplatin; for one prior treatment, exposure to a VEGF/VEGF receptor (VEGFR) inhibitor is optional.
  3. CRC (1L) Cohort B3: Participants must not have had prior chemotherapy for advanced or metastatic disease. Participant could have received adjuvant chemotherapy or adjuvant chemo-radiotherapy, as long as relapse did not occur within 6 months of complete of adjuvant therapy. If so, the relapse within 6 months would be considered a line of therapy; the participant would be considered 2L, and not 1L.
  4. NSCLC (1L) Cohort C2: Participants must have a TPS ≥50% and must not have received prior systemic treatment setting.
  5. NSCLC (1L) Cohort C3: Participants with any TPS and must not have received prior systemic treatment setting.

Exclusion Criteria:

* Active or history of pneumonitis/ILD, pulmonary fibrosis requiring treatment with systemic steroid therapy, including evidence to suggest pneumonitis/ILD on baseline assessments including imaging.
* Diagnosis of immunodeficiency or an active autoimmune disease that require systemic treatment with chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy in the past 2 years.
* Sensory peripheral neuropathy ≥Grade 2 (Part 2 only)
* Active or history of clinically significant gastrointestinal (GI) disease (including but not limited to inflammatory GI disease \[eg, ulcerative colitis, Crohn's disease, inflammatory bowel disease\], immune-mediated colitis, peptic ulcer disease, GI bleeding, chronic diarrhea) and other conditions that are unresolved and/or may increase the risk associated with study participation or study treatment administration.
* Active bleeding disorder, including GI bleeding, as evidenced by hematemesis, significant hemoptysis or melena in the past 6 months.
* Major surgery or completion of radiation therapy ≤4 weeks prior to enrollment/randomization or radiation therapy that included \>30% of the bone marrow.
* Known sensitivity or contraindication to any component of study intervention (PF-07985045, gemcitabine, nab-paclitaxel, cetuximab, bevacizumab, FOLFOX, 5-FU, pembrolizumab, sasanlimab, cisplatin, carboplatin, pemetrexed, SHP2 inhibitor(s).
* Hematologic abnormalities.
* Renal impairment.

  * Hepatic abnormalities.

Where this trial is running

Fayetteville, Arkansas and 9 other locations

• Highlands Oncology Group — Fayetteville, Arkansas, United States (Not_yet_recruiting)
• Highlands Oncology Group — Rogers, Arkansas, United States (Not_yet_recruiting)
• Highlands Oncology Group — Springdale, Arkansas, United States (Not_yet_recruiting)
• City of Hope (City of Hope National Medical Center, City Of Hope Medical Center) — Duarte, California, United States (Not_yet_recruiting)
• Brigham and Women's Hospital — Boston, Massachusetts, United States (Not_yet_recruiting)
• Dana-Farber Cancer Institute — Boston, Massachusetts, United States (Not_yet_recruiting)
• DFCI Chestnut Hill — Newton, Massachusetts, United States (Not_yet_recruiting)
• Columbia University Irving Medical Center — New York, New York, United States (Not_yet_recruiting)
• The University of Texas MD Anderson Cancer Center — Houston, Texas, United States (Not_yet_recruiting)
• Pan American Center for Oncology Trials, LLC — Rio Piedras, Puerto Rico (Recruiting)

Study contacts

• Study coordinator: Pfizer CT.gov Call Center

Conditions Carcinoma, Pancreatic Ductal; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Ductal, Pancreatic; Duct-Cell Carcinoma of the Pancreas; Duct-Cell Carcinoma, Pancreas; Ductal Carcinoma of the Pancreas; Pancreatic Duct Cell Carcinoma